ALS (motor neurone disease): who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• TDP-43 8
• SOD1 8
• C9orf72 4
• NRF2 0
• STING 0
• SIRT1 0
• HDAC 0
• NLRP3 0
• TREM2 0
• BDNF 0
• MAPK 0
• APOE 0
• GLP-1 0
• HMGB1 0
• mTOR 0
• SMN1 0
• TP53 0
• AMPK 0
• BTK 1
• CXCR4 0
• HSP90 1
• JAK 0
• JNK 0
• LAG-3 0
• NMDA 0
• PI3K 0
• PINK1 0
• PPAR 0
• TFEB 0
• TNF 0
• AKT 0
• APP 0
• ATM 0
• AXL 0
• BCL-2 0
• CDK4/6 0
• COX-2 0
• CSF1R 0
• ERK 0
• GPX4 0
• IL-1 0
• MAPT 0
• PARP 0
• PCSK9 0
• PDE4 1
• PSEN1 0
• PTEN 0
• SNCA 0
• STK11 0
• TLR4 0
• TTR 0
• VEGF 0
• YAP 0

24 of 30+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NINDS · F31

  Uncovering the Role of Perisynaptic Schwann Cells in C9ORF72 Amyotrophic Lateral Sclerosis Susceptibility and Progression

  University of Chicago· Chicago, United States· US$50,114 awarded in fiscal year 2026· until Sept 2029

• NIH NCI · F31

  Deciphering RNA Zipcodes: A Novel Framework for Subcellular Localization Element Annotation

  Baylor College of Medicine· Houston, United States· US$50,114 awarded in fiscal year 2026· until Sept 2029

• NIH NINDS · F31

  Nuclear-cytoskeletal coupling through the giant KASH protein ANC-1 maintains neuronal mechanical integrity during aging

  University of California at Davis· Davis, United States· US$43,471 awarded in fiscal year 2026· until Nov 2028

• NIH NIDCD · F31

  An articulatory brain-computer interface approach for restoring expressive communication to people with paralysis

  University of California at Davis· Davis, United States· US$43,752 awarded in fiscal year 2026· until Sept 2029

• NIH NINDS · R56

  Unraveling Mechanisms Governing Cell Clearance Deficits in C9ORF72-ALS/FTD

  University of Missouri-Columbia· Columbia, United States· US$539,427 awarded in fiscal year 2026· until Aug 2027

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Curation, Integration, Modelling and Rational Design of Small Molecule Amyloid Inhibitors (AmyStoppers)

  Vilniaus Universitetas· Vilnius, Lithuania· EU contribution €196,976· until Mar 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  From Stool to Solutions: Diagnose, Decode, Disruptors, and Deliver Interventions for the Human Gut Microbiota in Neurodegenerative Diseases. (GUT-4D)

  Universita Degli Studi del Piemonte Orientale Amedeo Avogadro· Vercelli, Italy· EU contribution €1,568,130· until Sept 2030· 8 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unraveling the impact of RNA-editing in neurodegeneration: a focus on TDP-43 related frontotemporal dementia. (NeuroEDIT)

  Asociacion Instituto de Investigacion Sanitaria Biogipuzkoa· Donostia-San Sebastian, Spain· EU contribution €194,075· until Aug 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  POLYMND: Polyamine dysregulation in Motor Neuron Disease as a targetable driver of astrocyte–neuron dysfunction

  The Chancellor Masters and Scholars of the University of Cambridge· Cambridge, United Kingdom· EU contribution €276,188· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Engineered Humanized Spinal Cord Construct for Advancing Health and Disease Research (SpineCraft)

  Fundacio Institut de Bioenginyeria de Catalunya· Barcelona, Spain· EU contribution €2,743,700· until Mar 2031

  The disease is named only in the funder's project summary, not in the title.

10 of 510 running projects, newest first. Listed amounts together: US$399.3m + €25.3m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders

  NCT01459302· University of Massachusetts, Worcester· Updated 19 Sept 2024

  “This study is not a clinical trial.”Registry text, quoted unchanged. Source

• Suspended

  SOD1 Kinetics Measurements in ALS Patients

  NCT03449212· Washington University School of Medicine· Updated 25 Jul 2024

  “COVID-19 pandemic”Registry text, quoted unchanged. Source

• Withdrawn

  Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)

  NCT05949294· Arrowhead Pharmaceuticals· Updated 17 Apr 2024

  “Company business decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms

  NCT04856982· Biogen· Source

• First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)

  NCT06351592· Regeneron Pharmaceuticals· Source

• A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)

  NCT07223723· Biogen· Source

• iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study

  NCT04744532· Kyoto University· Source

• A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)

  NCT07259980· Biogen· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 7
• Organoids 7
• Mendelian Randomization Analysis 18
• CRISPR-Cas Systems 8
• Gene Expression Profiling 23
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 6
• Exome Sequencing 6
• Proteomics 29
• Metabolomics 7
• Mass Spectrometry 6
• Flow Cytometry 2
• Immunohistochemistry 5
• Liquid Biopsy 2
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 57
• Machine Learning 18
• Deep Learning 7
• Cohort Studies 80
• Genome-Wide Association Study 24

• Neurotransmitter-defined cerebral vulnerability patterns in frontotemporal lobar degeneration (FTLD).

  J Neurol, Oct 2026

• Neurofilaments support the differentiation of amyotrophic lateral sclerosis from degenerative cervical myelopathy.

  J Neural Transm (Vienna), Oct 2026

• Neuroimaging signatures of facial onset sensory and motor neuronopathy (FOSMN).

  J Neurol, Oct 2026

• Cortical Motor Hierarchy Disruption Is Associated With Functional Status in Early Amyotrophic Lateral Sclerosis.

  J Cachexia Sarcopenia Muscle, Oct 2026

• Potential Roles of Neuroimaging in Motor Neuron Disease.

  Curr Neurol Neurosci Rep, Sept 2026

• VRK1-Related Motor Neuropathy With Upper Motor Neuron Signs and Selective Muscle Involvement.

  J Peripher Nerv Syst, Sept 2026

• Dropped head syndrome as the sole presenting manifestation of probable post-cytomegalovirus immune-mediated brainstem encephalitis in an immunocompetent woman: a case report.

  Front Immunol, Aug 2026

• Magnetic resonance imaging applications to amyotrophic lateral sclerosis beyond the central nervous system.

  Front Neurol, Aug 2026

• Peripheral nervous system involvement accompanies central nervous system involvement in anti-N-methyl-D-aspartate receptor encephalitis.

  Front Immunol, Aug 2026

• Frontotemporal dementia with right temporal predominance: a clinical comparison with left-predominant FTD.

  J Neurol, Aug 2026

See which targets of this disease your abstract mentions, and go to the people working on them.